Under these conditions, NSAIDs block activation of the NF-κB pathway and there is some evidence from in vitro and animal studies to suggest that inhibition of IκB degradation is responsible for the anti-tumour effect of the agents [66,67,68] (Figure 1). This evidence concerns the gene NFKB1 and neoplasm.